Pharmacological profile of 5-hydroxytryptamine-induced inhibition on the pressor effect elicited by sympathetic stimulation in long-term diabetic pithed rats

European Journal of Pharmacology

Volumn 643, Issue 1, 2010, Pages 70-77

  Morán, Asunción ^a   Restrepo, Beatriz ^a,b   de Urbina, Ana Vega Ortiz ^a   García, Mónica ^a   Martín, Maria Luisa ^a   Román, Luis San ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b UNIVERSIDAD DEL QUINDÍO   (Colombia)

Author keywords

5 Hydroxytryptamine; Long term experimental diabetes; Pre junctional inhibition

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 (4 METHYL 1 PIPERAZINYL) 7 TRIFLUOROMETHYLPYRROLO[1,2 A]QUINOXALINE; 5 CARBOXAMIDOTRYPTAMINE MALEATE; 6 CHLORO 2 (1 PIPERAZINYL)PYRAZINE; ALLOXAN; ALPHA METHYLSEROTONIN; ATROPINE; BW 273C 86; METITEPINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [4 [5 [3 (2 AMINOETHYL) 1H INDOL 5 YL] 1,2,4 OXADIAZOL 3 YL]BENZYL]METHANESULFONAMIDE; NORADRENALIN; PHENYLBIGUANIDE; SEROTONIN; SEROTONIN 1 RECEPTOR; SEROTONIN 1A RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SPIPERONE; UNCLASSIFIED DRUG;

ADRENERGIC STIMULATION; ALLOXAN DIABETES MELLITUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ELECTROSTIMULATION; HYPERGLYCEMIA; INHIBITION KINETICS; MALE; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RAT;

EID: 77955054582     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.06.013     Document Type: Article

References (53)

1. Agrawal D.K., Bhimji S., Mcneill J.H. Effect of chronic experimental diabetes on vascular smooth muscle function in rabbit carotid artery. J. Cardiovasc. Pharmacol. 1987, 9:584-593.
2. Andersson D., Brunkwall J., Bergqvist D., Edvinsson E. Diminished contractile responses to neuropeptide Y of arteries from diabetic rats. J. Auton. Nerv. Syst. 1992, 37:215-222.
3. 2 receptor subtypes: a family reunited?. TIPs 1995, 16:105-110.
4. Bühlen M., Fink K., Böing C., Göthert M. Evidence for presynaptic location of inhibitory 5-HT1D beta-like autoreceptors in the guinea-pig brain cortex. Naunyn Sch. Arc. Pharmacol. 1996, 353:281-289.
5. Castillo C., Ibarra M., Terron J.A., Villalon C.M. Direct effects of indorenate and 8-OH-DPAT on the blood pressure of pithed rats. Drug Develop. Res. 1994, 33:20-25.
6. Chan N.N., Vallance P., Colhoun H.M. Nitric oxide and vascular responses in type I diabetes. Diabetologia 2000, 43:1137-1147.
7. 3 receptor by 1-phenylbiguanide increases dopamine release in the rat nucleus accumbens. Brain Res. 1991, 543:354-357.
8. Cicin-Sain L., Jernej B. Reduction of gastrointestinal serotonin in alloxan-diabetic rats: reversal by 5 hydroxytryptophan treatment. Behav. Brain Res. 1996, 73:285-288.
9. De Vriese A.S., Verbeuren T.J., Van de Voorde J., Lameire N.H., Vanhoutte P.M. Endothelial dysfunction in diabetes. Br. J. Pharmacol. 2000, 130:963-974.
10. Docherty J.R. Investigation of cardiovascular 5-HT receptors subtypes in the rat. Naunyn Schmied Arch. Pharmacol. 1988, 337:1-8.
11. Doggrell S.A. Sarpogrelate: cardiovascular and renal clinical potential. Expert Opin. Investig. Drugs 2004, 13:865-874.
12. 1 receptor antagonists. J. Auton. Pharmacol. 2000, 20:313-323.
13. Fink K.B., Göthert M. 5-HT receptor regulation of neurotransmitter release. Pharmacol. Rev. 2007, 59:360-417.
14. García M., Morán A., Calama E., Martín M.L., Bartherlmebs M., San Román L. Diabetes-induced changes in the 5-hydroxytryptamine inhibitory receptors involved in the pressor effect elicited by sympathetic stimulation in the pithed rat. Br. J. Pharmacol. 2005, 145:593-601.
15. García M., Morán A., Martín M.L., Barthelmebs M., San Román L. The nitric oxide synthesis/pathway mediates the inhibitory serotoninergic responses of the pressor effect elicited by sympathetic stimulation in diabetic pithed rats. Eur. J. Pharmacol. 2006, 537:126-134.
16. Gillespie J.S., Muir J.C. A method of stimulating the complete sympathetic outflow from the spinal cord to blood vessels in the pithed rat. Br. J. Pharmacol. Chemother. 1967, 30:78-87.
17. Gradin K., Dahlof C., Persson B. A low dietary sodium intake reduces neuronal noradrenaline release and the blood pressure in spontaneously hypertensive rats. Naunyn Schmied Arch. Pharmacol. 1986, 332:364-369.
18. Hemrick-Luecke S.K., Fuller R.W. Involvement of 5-HT2A receptors in the elevation of rat serum corticosterone concentrations by quipazine and MK-212. Eur. J. Pharmacol. 1996, 311:207-211.
19. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., Humphrey P.P. International Union of Pharmacology classification of receptors of 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 1994, 46:157-203.
20. Ireland S.J., Jordán C.C. Pharmacological characterization of 5-hydroxytryptamine-induced hyperpolarization of the rat superior cervical ganglion. Br. J. Pharmacol. 1987, 92:417-427.
21. 1D receptors mediate inhibition of sympathetic ganglionic transmission in anaesthetized cats. Br. J. Pharmacol. 1995, 116:1715-1717.
22. Kasho M., Sakai M., Sasahara T., Anami Y., Matsumura T., Takemura T., Matsuda H., Kobori S., Shichiri M. Serotonin enhances the production of type IV collagen by human mesangial cells. Kidney Int. 1998, 54:1083-1092.
23. Kennett G.A., Wood M.D., Bright F., Cilia J., Piper D.C., Gager T., Thomas D., Baxter G.S., Forbes I.T., Ham P. Effects of the 5-HT2B receptor agonist, BW 723C86, on three rat models of anxiety. Br. J. Pharmacol. 1996, 117:1443-1450.
24. Kennett G.A., Wood M.D., Bright F., Trail B., Riley G., Holland V., Avenell K.Y., Stean T., Upton N., Bromidge S., Forbes I.T., Brown A.M., Middlemiss D.N., Blackburn T.P. BW 723C86, a 5-HT2B receptor agonist, causes hyperphagia and reduced grooming in rats. Neuropharmacol. 1997, 36:233-240.
25. Kogan H.A., Marsden C.A., Fone K.C. DR 4004, a putative 5-HT7 receptor antagonist, also has functional activity at the dopamine receptor. Eur. J. Pharmacol. 2002, 449:105-112.
26. Leysen J.E., Gommeren W., Van Gompel P., Wynants J., Janssen P.F., Laduron P.M. Receptor-binding properties in vitro and in vivo of ritanserin: a very potent and long acting serotonin-S2 antagonist. Mol. Pharmacol. 1985, 27:600-611.
27. McGrath M.A. 5-HT and neurotransmitter release in canine blood vessels. Cir. Res. 1997, 41:428-435.
28. Miranda F.J., Alabadi J.A., Llorens S., Ruiz de Apodaca R.F., Centeno J.M., Alborch E. Diabetes-induced changes in endothelial mechanisms implicated in rabbit carotid arterial response to 5-hydroxytryptamine. Eur. J. Pharmacol. 2000, 401:397-402.
29. Miranda F.J., Alabadi J.A., Llorens S., Ruiz de Apodaca R.F., Centeno J.M., Alborch E. Experimental diabetes induces hyperreactivity of rabbit renal artery to 5-hydroxytryptamine. Eur. J. Pharmacol. 2002, 439:121-127.
30. Morán A., Velasco C., Salvador T., Martín M.L., San Román L. Inhibitory 5-hydroxytryptamine receptors involved in pressor effects obtained by stimulation of sympathetic outflow from spinal cord in pithed rats. Br. J. Pharmacol. 1994, 113:1358-1362.
31. 1 receptors that mediate the inhibition of pressor effects elicited by sympathetic stimulation in the pithed rats. Br. J. Pharmacol. 1998, 123:1205-1213.
32. Morán A., de Urbina A.V., Martín M.L., Rodríguez-Barbero A., San Román L. Characterization of the contractile 5-hydroxytryptamine receptor in the autoperfused kidney of L-NAME hypertensive rats. Eur. J. Pharmacol. 2009, 620:90-96.
33. Ni W., Zhou H., Diaz J., Murphy D.L., Haywood J.R., Watts S.W. Lack of the serotonin transporter does not prevent mineralocorticoid hypertension in rat and mouse. Eur. J. Pharmacol. 2008, 589:225-227.
34. 2 receptor antagonist sarpogrelate reduces urinary and plasma levels of thromboxane A2 and urinary albumin excretion in non-insulin-dependent diabetes mellitus patients. Clin. Exp. Pharmacol. Physiol. 1999, 26:461-464.
35. Ogawa S., Takeuchi K., Sugimura K., Sato C., Fukuda M., Lee R., Ito S., Sato T. Profiles of R 9654, the active from of novel 5-HT2A receptor antagonist R 102444. Eur. J. Pharmacol. 2002, 457:107-112.
36. Ralevic V., Belai A., Burnstock G. Impaired sensory-motor nerve function in the isolated mesenteric arterial bed of streptozotocin-diabetic and ganglioside-treated streptozotocin-diabetic rats. Br. J. Pharmacol. 1993, 110:1105-1111.
37. Ramage A.G., Villalon C.M. 5-Hydroxytryptamine and cardiovascular regulation. Trends Pharmacol. Sci. 2008, 29:472-481.
38. Richardson B.P., Engel G., Donatsch P., Stadler P.A. The pharmacology and function of 5-HT3 receptors. Trends Neurosci. 1986, 9:424-428.
39. Rodgers R.J., Cole J.C. Anxiolytic-like effect of (S)-Way 100135, a 5HT1A receptor antagonist in the murine. Elevated plus-maze test. Eur. J. Pharmacol. 1994, 261:321-330.
40. Roth B.L., Craigo S.C., Choudhar M.S., Uluer A., Monsma F.J., Shen Y., Meltzer H.Y., Sibley D.R. Binding of typical and atypical antipsychotic agents to 5-hidroxytryptamine 6 and 5-hydroxytryptamine-7 receptors. J. Pharmacol. Exp. Ther. 1994, 268:1403-1410.
41. 2 receptors in the rat brain. Life Sci. 1997, 60:1393-1397.
42. Taylor P.D., Oon B.B., Thomas C.R., Poston L. Prevention by insulin treatment of endothelial dysfunction but not enhanced noradrenaline-induced contractility in mesenteric resistance arteries from streptozotocin-induced diabetic rats. Br. J. Pharmacol. 1994, 111:35-41.
43. Tomkins D.M., O'Neill M.F. Effect of 5-HT(1B) receptor ligand on self-administration of ethanol in an operant procedure in rats. Pharmacol. Biochem. Behav. 2000, 66:129-136.
44. Umrani D.N., Bodiwala D.N., Goyal R.K. Effect of sarpogrelate on altered STZ-diabetes induced cardiovascular responses to 5-hydroxytryptamine in rats. Mol. Cel. Biochem. 2003, 249:53-57.
45. Vanhoutte P.M. Endothelium and responsiveness of vascular smooth muscle. J. Hypertens. 1987, 5:115-120.
46. Vanhoutte P.M. Say NO to ET. J. Auton. Nery. Syst. 2000, 81:271-277.
47. Villalón C.M., Centurión D. Cardiovascular responses produced by 5-hydroxytryptamine a pharmacological update on the receptor/mechanisms involved and therapeutic implications. Naunyn-Schmied Arch. Pharmacol. 2007, 376:45-63.
48. Villalón C.M., Contreras J., Ramirez-San Juan E., Castillo C., Perusquia M., Lopez-Munoz F.J., Terron J.A. 5-Hydroxytryptamine inhibits pressor responses to preganglionic sympathetic nerve stimulation in pithed rats. Life Sci. 1995, 57:803-812.
49. Villalón C.M., Contreras J., Ramirez-San Juan E., Castillo C., Perusquía M., Terrón J.A. Characterization of prejunctional 5-HT receptors mediating inhibition of sympathetic vasopressor responses in the pithed rats. Br. J. Pharmacol. 1995, 116:3330-3336.
50. Villalón C.M., Contreras J., Ramírez-San Juan E., Terrón J.A. 5-HT receptors mediating inhibition of pressor responses to electrical sympathetic stimulation in pithed rats. Br. J. Pharmacol. 1995, 114:161.
51. 1D subtypes. Br. J. Pharmacol. 1998, 124:1001-1011.
52. Wood M., Chaubey M., Atkinson P., Thomas D.R. Antagonist activity of meta-chlorophenylpiperazine and partial agonist activity of 8-OH-DPAT at the 5-HT(7) receptor. Eur. J. Pharmacol. 2000, 12:1-8.
53. Yoshitake T., Kehr J. Differential effects of (R)-, (R, S) and (S)-8-hydroxy-2-(di-n-propylamino)tetralin on hippocampal serotonin release and induction of hypothermia in awake rats. Life Sci. 2004, 74:288-265.